TWI609686B - 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 - Google Patents
使用馬賽替尼治療以預測因子所識別的癌症患者亞群 Download PDFInfo
- Publication number
- TWI609686B TWI609686B TW102136110A TW102136110A TWI609686B TW I609686 B TWI609686 B TW I609686B TW 102136110 A TW102136110 A TW 102136110A TW 102136110 A TW102136110 A TW 102136110A TW I609686 B TWI609686 B TW I609686B
- Authority
- TW
- Taiwan
- Prior art keywords
- pain
- treatment
- patient
- patients
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ??12306214.3 | 2012-10-04 | ||
| EP12306214 | 2012-10-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201414475A TW201414475A (zh) | 2014-04-16 |
| TWI609686B true TWI609686B (zh) | 2018-01-01 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102136110A TWI609686B (zh) | 2012-10-04 | 2013-10-04 | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (https=) |
| EP (1) | EP2903616B8 (https=) |
| JP (1) | JP6234466B2 (https=) |
| KR (1) | KR102149483B1 (https=) |
| CN (1) | CN104968347A (https=) |
| AR (1) | AR092899A1 (https=) |
| AU (1) | AU2013326463B2 (https=) |
| BR (1) | BR112015007144A2 (https=) |
| CA (1) | CA2886979C (https=) |
| DK (1) | DK2903616T3 (https=) |
| EA (1) | EA037368B1 (https=) |
| ES (1) | ES2656640T3 (https=) |
| IL (1) | IL238107B (https=) |
| MX (1) | MX369999B (https=) |
| NZ (1) | NZ706420A (https=) |
| SG (1) | SG11201502626PA (https=) |
| SI (1) | SI2903616T1 (https=) |
| TW (1) | TWI609686B (https=) |
| WO (1) | WO2014053650A1 (https=) |
| ZA (1) | ZA201503054B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015049377A1 (en) * | 2013-10-04 | 2015-04-09 | Ab Science | Method for determining the prognosis of pancreatic cancer |
| AU2015257658A1 (en) * | 2014-05-08 | 2016-11-10 | Oncoethix Gmbh | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
| US20170304286A1 (en) * | 2014-10-24 | 2017-10-26 | Launx Biomedical Co., Ltd. | New indication of paroxetine pharmaceutical composition for treating cancer |
| US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
| PE20231050A1 (es) | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| SG11201808106YA (en) * | 2016-03-25 | 2018-10-30 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| BR112019015974A2 (pt) * | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| IL276398B2 (en) * | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| US20210398672A1 (en) * | 2018-10-29 | 2021-12-23 | Northwestern University | Big Data-Driven Personalized Management of Chronic Pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| CN111759857A (zh) * | 2020-06-30 | 2020-10-13 | 宁波市微循环与莨菪类药研究所 | Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| WO2007015935A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| US20100143935A1 (en) * | 2006-12-01 | 2010-06-10 | Apocell, Inc. | c-KIT Phosphorylation in Cancer |
| ES2606505T3 (es) | 2007-01-12 | 2017-03-24 | Ab Science | Tratamiento de combinación de cánceres sólidos con antimetabolitos e inhibidores de tirosina quinasa |
| US8153792B2 (en) | 2007-02-13 | 2012-04-10 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
| US20120264639A1 (en) | 2009-11-04 | 2012-10-18 | Jen Jen Yeh | Methods and compositions for predicting survival in subjects with cancer |
| WO2012170640A1 (en) * | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active Active
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja active Active
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en not_active Ceased
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en not_active IP Right Cessation
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh not_active IP Right Cessation
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
Also Published As
| Publication number | Publication date |
|---|---|
| EA037368B1 (ru) | 2021-03-19 |
| JP6234466B2 (ja) | 2017-11-22 |
| KR20150092739A (ko) | 2015-08-13 |
| NZ706420A (en) | 2018-08-31 |
| CN104968347A (zh) | 2015-10-07 |
| MX2015004264A (es) | 2015-10-12 |
| KR102149483B1 (ko) | 2020-08-28 |
| EP2903616A1 (en) | 2015-08-12 |
| SG11201502626PA (en) | 2015-05-28 |
| BR112015007144A2 (pt) | 2017-12-12 |
| MX369999B (es) | 2019-11-28 |
| ES2656640T3 (es) | 2018-02-27 |
| AU2013326463A1 (en) | 2015-04-16 |
| DK2903616T3 (da) | 2018-01-29 |
| EP2903616B1 (en) | 2017-12-13 |
| AR092899A1 (es) | 2015-05-06 |
| CA2886979C (en) | 2021-01-05 |
| JP2015532296A (ja) | 2015-11-09 |
| CA2886979A1 (en) | 2014-04-10 |
| US10238649B2 (en) | 2019-03-26 |
| IL238107B (en) | 2018-03-29 |
| AU2013326463B2 (en) | 2018-01-18 |
| ZA201503054B (en) | 2016-11-30 |
| TW201414475A (zh) | 2014-04-16 |
| WO2014053650A1 (en) | 2014-04-10 |
| US20150272945A1 (en) | 2015-10-01 |
| EA201500373A1 (ru) | 2016-02-29 |
| SI2903616T1 (en) | 2018-02-28 |
| EP2903616B8 (en) | 2018-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI609686B (zh) | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 | |
| Schuler et al. | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial | |
| Hata et al. | Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection | |
| CA2850175C (en) | Biomarkers for predicting sensitivity to cancer treatments | |
| KR20150131312A (ko) | 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료 | |
| EP3638242A1 (en) | Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| Ichihara et al. | Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations | |
| US11136625B2 (en) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same | |
| Harrison et al. | Treatment of Glioblastoma in the Elderly | |
| US20200071765A1 (en) | Cancer treatments and methods of selecting same | |
| Antonacopoulou et al. | Integrin beta‐3 L33P: a new insight into the pathogenesis of chronic oxaliplatin‐induced peripheral neuropathy? | |
| US20180263979A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| Lièvre et al. | RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014 | |
| JP2017511341A (ja) | Ｎｒａｓ変異癌の処置における使用のためのｅｇｆｒ阻害剤とｍｅｋ阻害剤の組合せ | |
| Li et al. | [Retracted] The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta‐Analysis | |
| US20170196880A1 (en) | Antitumor activity of multi-kinase inhibitors in triple negative breast cancer | |
| Nagarajan et al. | 0034 genetic variants for obstructive sleep apnea identified after modeling interactions with daytime sleepiness | |
| Yi et al. | Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors | |
| CN115667552A (zh) | 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷 | |
| Nazarov et al. | Effects of n-Myc and c-Myc on the expression of p53 family members and their transcriptional targets in human neuroblastoma cells | |
| JP2020114857A (ja) | Ｒａｆ阻害剤及びタキサンの組み合わせ | |
| JP2025507955A (ja) | 癌の治療のための精密療法 | |
| Wang et al. | Therapeutic effect of gefitinib in advanced non-small cell lung cancer and its effect on the EGFR level in peripheral blood | |
| Zhang et al. | Analysis of an unselected patient cohort with advanced colorectal carcinoma from a maximum care center | |
| Hill | Biological mechanisms of disease relapse in childhood medulloblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |